Retrophin, Inc. (RTRX)
(Delayed Data from NSDQ)
$19.72 USD
+0.61 (3.19%)
Updated May 3, 2019 04:00 PM ET
After-Market: $19.75 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Travere Therapeutics, Inc. [RTRX]
Reports for Purchase
Showing records 21 - 35 ( 35 total )
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Revenue Guidance Upped; Pipeline Updated; Reiterate Focus Pick
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
The Ever Building Portfolio; Reiterate Focus Pick; Target Upped to $51
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Compelling 2014 Story; Adding to Focus List; Target to $41
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
In-licensing, Acquisition Build CNS Pipeline; Near-term Revenue is Bonus
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q13 Results; "Going Pivotal" Soon; Expect Fast Answers; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Travere Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Efficiency and Rapidity; Two Great Qualities; Initiating at Buy
Provider: Roth Capital Partners, Inc.
Analyst: PANTGINIS J